摘要
Fibroblast growth factor receptors (FGFRs) have emerged as promising targets for anticancer therapy.In this study,we synthesized and evaluated the biological activity of 66 pyrazolo[3,4-d]pyridazinone derivatives.Kinase inhibition,cell proliferation,and whole blood stability assays were used to evaluate their activity on FGFR,allowing us to explore structureàactivity relationships and thus to gain understanding of the structural requirements to modulate covalent inhibitors’selectivity and reactivity.Among them,compound 10h exhibited potent enzymatic activity against FGFR and remarkably inhibited proliferation of various cancer cells associated with FGFR dysregulation,and suppressed FGFR signaling pathway in cancer cells by the immunoblot analysis.Moreover,10h displayed highly potent antitumor efficacy (TGI Z 91.6%,at a dose of 50 mg/kg) in the FGFR1-amplified NCI-H1581 xenograft model.
基金
financial support from the National Natural Science Foundation of China (81620108027 and21632008 to Hong Liu, 81773634 to Mingyue Zheng and81773762 to Jing Ai)
National Science&Technology Major Project “Key New Drug Creation and Manufacturing Program”(2018ZX09711002, China)
the Major Project of Chinese National Programs for Fundamental Research and Development(2015CB910304 to Hong Liu)
“Personalized Medicinesd Molecular Signature-based Drug Discovery and Development”
Strategic Priority Research Pro-gram of the Chinese Academy of Sciences (XDA12050201 to Mingyue Zheng,XDA12020000 to Meiyu Geng and XDA12020103 to Jing Ai)
The Natural Science Foundation of China for Innovation Research Group (81821005 to Meiyu Geng, China)
The Collaborative Innovation Cluster Project of Shanghai Municipal Commission of Health and Family Planning (2020CXJQ02 to Meiyu Geng,China)。
